Figure 6.

Proportion of patients with 24-week confirmed disability progression over 2 years (time to disability progression).

Disability progression is defined as ≥1.0 point increase on the EDSS from a baseline EDSS ≥1.0 sustained for 24 weeks or ≥1.5 point increase on the EDSS from a baseline EDSS of 0 sustained for 24 weeks. Analyses were conducted by combining patients who received placebo in Year 1 and either peginterferon beta-1a every 2 or 4 weeks in Year 2 as one group (delayed treatment).

^aBased on a Cox proportional hazards model, adjustment for baseline EDSS and age (<40 vs. ≥40).